238 related articles for article (PubMed ID: 26170632)
1. Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
Gozzi GJ; Bouaziz Z; Winter E; Daflon-Yunes N; Honorat M; Guragossian N; Marminon C; Valdameri G; Bollacke A; Guillon J; Pinaud N; Marchivie M; Cadena SM; Jose J; Le Borgne M; Di Pietro A
Drug Des Devel Ther; 2015; 9():3481-95. PubMed ID: 26170632
[TBL] [Abstract][Full Text] [Related]
2. Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
Jabor Gozzi G; Bouaziz Z; Winter E; Daflon-Yunes N; Aichele D; Nacereddine A; Marminon C; Valdameri G; Zeinyeh W; Bollacke A; Guillon J; Lacoudre A; Pinaud N; Cadena SM; Jose J; Le Borgne M; Di Pietro A
J Med Chem; 2015 Jan; 58(1):265-77. PubMed ID: 25272055
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
4. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
5. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.
Valdameri G; Pereira Rangel L; Spatafora C; Guitton J; Gauthier C; Arnaud O; Ferreira-Pereira A; Falson P; Winnischofer SM; Rocha ME; Tringali C; Di Pietro A
ACS Chem Biol; 2012 Feb; 7(2):322-30. PubMed ID: 22039929
[TBL] [Abstract][Full Text] [Related]
6. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
7. Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).
Sim HM; Lee CY; Ee PL; Go ML
Eur J Pharm Sci; 2008 Nov; 35(4):293-306. PubMed ID: 18725288
[TBL] [Abstract][Full Text] [Related]
8. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
9. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
Valdameri G; Genoux-Bastide E; Peres B; Gauthier C; Guitton J; Terreux R; Winnischofer SM; Rocha ME; Boumendjel A; Di Pietro A
J Med Chem; 2012 Jan; 55(2):966-70. PubMed ID: 22165858
[TBL] [Abstract][Full Text] [Related]
10. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
Ahmed-Belkacem A; Pozza A; Muñoz-Martínez F; Bates SE; Castanys S; Gamarro F; Di Pietro A; Pérez-Victoria JM
Cancer Res; 2005 Jun; 65(11):4852-60. PubMed ID: 15930306
[TBL] [Abstract][Full Text] [Related]
11. Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
Winter E; Devantier Neuenfeldt P; Chiaradia-Delatorre LD; Gauthier C; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
J Med Chem; 2014 Apr; 57(7):2930-41. PubMed ID: 24611893
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles.
Kita DH; Guragossian N; Zattoni IF; Moure VR; Rego FGM; Lusvarghi S; Moulenat T; Belhani B; Picheth G; Bouacida S; Bouaziz Z; Marminon C; Berredjem M; Jose J; Gonçalves MB; Ambudkar SV; Valdameri G; Le Borgne M
Sci Rep; 2021 Jan; 11(1):1788. PubMed ID: 33469044
[TBL] [Abstract][Full Text] [Related]
13. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
Juvale K; Pape VF; Wiese M
Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
Winter E; Lecerf-Schmidt F; Gozzi G; Peres B; Lightbody M; Gauthier C; Ozvegy-Laczka C; Szakacs G; Sarkadi B; Creczynski-Pasa TB; Boumendjel A; Di Pietro A
J Med Chem; 2013 Dec; 56(24):9849-60. PubMed ID: 24304387
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
17. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
Darby RA; Unsworth A; Knapp S; Kerr ID; Callaghan R
Cancer Chemother Pharmacol; 2015 Oct; 76(4):853-64. PubMed ID: 26351135
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
19. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
[TBL] [Abstract][Full Text] [Related]
20. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Tan KW; Cooney J; Jensen D; Li Y; Paxton JW; Birch NP; Scheepens A
Mol Nutr Food Res; 2014 Nov; 58(11):2099-110. PubMed ID: 25044854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]